# Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

> **NCT06062953** · PHASE2,PHASE3 · RECRUITING · sponsor: **Lone Baandrup** · enrollment: 255 (estimated)

## Conditions studied

- Psychiatric Disorders
- Insomnia

## Interventions

- **DRUG:** Melatonin
- **DRUG:** Quetiapine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06062953
- **Lead sponsor:** Lone Baandrup
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-18
- **Primary completion:** 2029-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 255 (ESTIMATED)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06062953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06062953, "Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06062953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*